Kiora Pharmaceuticals, Inc.
kiorapharma.comWhat Do They Do?
Develops small-molecule therapies for retinal diseases, including candidates aimed at restoring vision for people with retinal degeneration and treating retinal inflammation.
10-K for FY2025, filed Mar 25, 2026We are a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of retinal diseases.View ↗
We are developing KIO-301, with an initial focus on patients with later stages of vision loss due to retinitis pigmentosa (collectively…View ↗
We are also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior…View ↗
Who Are Their Customers?
Kiora works with pharmaceutical partners that receive development and commercialization rights in defined territories; where it lacks a partner, it may seek another partner or sell directly to physicians.
10-K for FY2025, filed Mar 25, 2026In May 2025, we entered into an exclusive option agreement (the "Option Agreement") with Senju Pharmaceutical Co., Ltd ("Senju"). Under the…View ↗
On January 25, 2024, we entered into an agreement with TOI, a sister company of Laboratories Théa, with respect to KIO-301. The agreement…View ↗
If KIO-104 or KIO-301 are approved by the FDA or regulatory bodies in other countries, for commercial sale, we may enter into additional…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 7, 2026
−$2.1MView ↗
- ▼ −3% (Loss)
- vs −$2.2M in Q2 FY2025
-
Aug 19, 2026
Licenses KIO-301 rights in South Korea to CKD
CKD will develop and commercialize KIO-301 in South Korea; Kiora may receive milestone payments and royalties.
Sources
8-K, filed Aug 19, 2026
Effective August 20, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) entered into an Exclusive License and Development Agreement (the…View ↗
Portfolio refocused
The earlier report described a medicine for autoimmune-related eye conditions and a corneal-healing product. The latest report says the corneal program ended and the autoimmune program is being considered for partnership, while development centers on retinal disease candidates.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 25, 2026In August 2023, we decided to halt development work on our anterior segment assets, specifically KIO-101 and KIO-201. In July 2024, we made…View ↗
–Continue clinical development of KIO-301 for which a Phase 2 clinical study is actively enrolling patients with mid to late-stage…View ↗
–Continue clinical development of KIO-104 for which a Phase 2 clinical study is actively enrolling patients with retinal inflammation due…View ↗
Loading...
